Virtus LifeSci Biotech Clinical Trials ETFNYSE Arca:BBC
- LAST PRICE25.26
- TODAY'S CHANGE (%)0.31 (1.25%)
- Bid / Lots24.26/ 62
- Ask / Lots25.81/ 58
- Open / Previous Close24.89 / 24.95
- Day Range
- 52 Week Range
- Volume1,103
- Overall Morningstar Rating1 out of 5 Starsout of 268 funds
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BBC |
|---|---|---|
| 09:32 ET | 503 | 24.89 |
| 09:39 ET | 126 | 25.072 |
| 11:44 ET | 250 | 24.808 |
| 12:16 ET | 100 | 24.9587 |
| 03:59 ET | 0 | 25.2614 |
Daily Premium/Discount
| Date | Daily Premium/Discount |
|---|---|
| 04/01/2024 | -0.26% |
| 04/02/2024 | -0.21% |
| 04/03/2024 | -0.21% |
| 04/04/2024 | -0.40% |
| 04/05/2024 | -0.13% |
| 04/09/2024 | -0.33% |
| 04/10/2024 | -0.03% |
| 04/11/2024 | -0.24% |
| 04/12/2024 | -0.15% |
| 04/15/2024 | -0.17% |
| 04/16/2024 | -0.19% |
| 04/17/2024 | -0.10% |
| 04/18/2024 | 0.04% |
| 04/19/2024 Largest Discount | -0.42% |
| 04/22/2024 | -0.16% |
| 04/23/2024 | 0.19% |
| 04/24/2024 | -0.02% |
| 04/25/2024 | -0.10% |
| 04/26/2024 | -0.11% |
| 04/29/2024 | -0.28% |
| 04/30/2024 | 0.14% |
| 05/01/2024 | 0.05% |
| 05/02/2024 | -0.13% |
| 05/03/2024 | 0.10% |
| 05/06/2024 | 0.02% |
| 05/07/2024 | 0.15% |
| 05/08/2024 | -0.23% |
| 05/09/2024 | -0.10% |
| 05/10/2024 | -0.24% |
| 05/13/2024 | -0.15% |
| 05/14/2024 | -0.04% |
| 05/15/2024 | -0.04% |
| 05/16/2024 | 0.19% |
| 05/17/2024 | -0.23% |
| 05/20/2024 | -0.18% |
| 05/21/2024 | -0.26% |
| 05/22/2024 | -0.15% |
| 05/23/2024 | -0.26% |
| 05/24/2024 | -0.10% |
| 05/28/2024 | 0.01% |
| 05/30/2024 | -0.25% |
| 05/31/2024 | -0.03% |
| 06/03/2024 | 0.01% |
| 06/04/2024 | 0.14% |
| 06/05/2024 | -0.09% |
| 06/06/2024 | 0.14% |
| 06/07/2024 | -0.06% |
| 06/10/2024 | -0.10% |
| 06/11/2024 | -0.01% |
| 06/12/2024 | 0.20% |
| 06/13/2024 | 0.05% |
| 06/14/2024 | -0.10% |
| 06/17/2024 Largest Premium | 1.02% |
| 06/18/2024 | 0.00% |
| 06/20/2024 | -0.22% |
| 06/21/2024 | -0.09% |
| 06/24/2024 | 0.04% |
| 06/25/2024 | 0.07% |
| 06/26/2024 | 0.05% |
| 06/27/2024 | -0.10% |
| US Stock | 89.5% |
|---|---|
| Non-US Stock | 8.3% |
| Cash | 2.2% |
| Convertible | 0 |
| Non-US Bond | 0 |
| Other | 0 |
| Healthcare | 97.8% |
|---|---|
| Basic Mat. | 0 |
| Communication Services | 0 |
| Consumer Cyclical | 0 |
| Consumer Defensive | 0 |
| Energy | 0 |
| Financial Serv.s | 0 |
| Industrials | 0 |
| Real Estate | 0 |
| Technology | 0 |
| Utilities | 0 |
| United States | 91.5% |
|---|---|
| Europe | 4.4% |
| Canada | 1.4% |
| Africa | 0 |
| Latin America | 0 |
| Asia/Oceania | 0 |
| Company Name sortable | Position sortable | Allocation sortable | Allocation sortable1 Month Change | Market Value sortable |
|---|---|---|---|---|
Avidity Biosciences Inc Ordinary Shares | Long | 2.8% | 0.00% | $301.0K |
Summit Therapeutics Inc Ordinary Shares | Long | 2.8% | 0.00% | $296.2K |
Viking Therapeutics Inc | Long | 2.8% | 0.00% | $292.0K |
Cullinan Therapeutics Inc | Long | 2.3% | 0.00% | $248.7K |
Dyne Therapeutics Inc Ordinary Shares | Long | 2.3% | 0.00% | $242.6K |
Novavax Inc | Long | 2.2% | 0.00% | $237.9K |
Vera Therapeutics Inc Class A | Long | 2.2% | 0.00% | $232.3K |
Spyre Therapeutics Inc | Long | 2.0% | 0.00% | $212.0K |
Merus NV | Long | 1.8% | 0.00% | $189.9K |
Apogee Therapeutics Inc | Long | 1.7% | 0.00% | $176.9K |
Reports
- ManagedInvestmentETF06/09/24
Morningstar ETF Report
The Morningstar ETF Report offers in-depth analyst research on exchange-traded funds to help you evaluate these investments and how they fit within a portfolio.
Morningstar Ratings
| Time Horizon | Star Rating |
|---|---|
| Overall Rating | 1 out of 5 Stars |
| 3 Year Rating | 1 out of 5 Stars |
| 5 Year Rating | 1 out of 5 Stars |
| 10 Year Rating | Not Rated |
Past performance is no guarantee of future results. The ratings reflect historical risk-adjusted performance, and the overall rating is derived from a weight average of the fund's 3, 5, and 10 year (Morningstar Rating) metrics.
Style Box is calculated only using the long position holdings of the portfolio.
Best Fit Index | Lifesci Biotchnlgy ClinicalTrials TR USD |
|---|---|
Category | |
Sponsor | Virtus ETF Advisers LLC |
Inception | December 16, 2014 |
The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index. Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
| Total Net Assets | $10.6M |
|---|---|
| Shares Out. | 400.0K |
| Net Asset Value (NAV) | $24.97 |
| Prem/Discount to NAV | -0.10% |
| P/E Ratio | --- |
| Dividend Yield | 0.33% |
| Dividend per Share | 0.08 USD |
| Ex-Dividend Date | 12/20/2023 |
| Dividend Payment Date | 12/29/2023 |
| Beta | --- |
| Morningstar Investment Style | Health |
| Equity Style | Small Cap Blend |
| Credit Quality / Duration | --- |
| Actual Management Fee | 0.79% |
|---|---|
| Actual Mgmt. Expense Ratio (MER) | 0.79% |